AIMS/HYPOTHESIS: Chronic inflammation in type 2 diabetes is proposed to affect islets as well as insulin target organs. However, the nature of islet inflammation and its effects on islet function in type 2 diabetes remain unclear. Moreover, the immune cell profiles of human islets in healthy and type 2 diabetic conditions are undefined. We aimed to investigate the correlation between proinflammatory cytokine expression, islet leucocyte composition and insulin secretion in type 2 diabetic human islets. METHODS: Human islets from organ donors with or without type 2 diabetes were studied. First and second phases of glucose-stimulated insulin secretion were determined by perifusion. The expression of inflammatory markers was obtained by quantitative PCR. Immune cells within human islets were analysed by FACS. RESULTS: Type 2 diabetic islets, especially those without first-phase insulin secretion, displayed higher CCL2 and TNFa expression than healthy islets. CD45(+) leucocytes were elevated in type 2 diabetic islets, to a greater extent in moderately functional type 2 diabetic islets compared with poorly functional ones, and corresponded with elevated ALOX12 but not with CCL2 or TNFa expression. T and B lymphocytes and CD11c(+) cells were detectable within both non-diabetic and type 2 diabetic islet leucocytes. Importantly, the proportion of B cells was significantly elevated within type 2 diabetic islets. CONCLUSIONS/ INTERPRETATION: Elevated total islet leucocyte content and proinflammatory mediators correlated with islet dysfunction, suggesting that heterogeneous insulitis occurs during the development of islet dysfunction in type 2 diabetes. In addition, the altered B cell content highlights a potential role for the adaptive immune response in islet dysfunction.
AIMS/HYPOTHESIS: Chronic inflammation in type 2 diabetes is proposed to affect islets as well as insulin target organs. However, the nature of islet inflammation and its effects on islet function in type 2 diabetes remain unclear. Moreover, the immune cell profiles of human islets in healthy and type 2 diabetic conditions are undefined. We aimed to investigate the correlation between proinflammatory cytokine expression, islet leucocyte composition and insulin secretion in type 2 diabetichuman islets. METHODS:Human islets from organ donors with or without type 2 diabetes were studied. First and second phases of glucose-stimulated insulin secretion were determined by perifusion. The expression of inflammatory markers was obtained by quantitative PCR. Immune cells within human islets were analysed by FACS. RESULTS:Type 2 diabetic islets, especially those without first-phase insulin secretion, displayed higher CCL2 and TNFa expression than healthy islets. CD45(+) leucocytes were elevated in type 2 diabetic islets, to a greater extent in moderately functional type 2 diabetic islets compared with poorly functional ones, and corresponded with elevated ALOX12 but not with CCL2 or TNFa expression. T and B lymphocytes and CD11c(+) cells were detectable within both non-diabetic and type 2 diabetic islet leucocytes. Importantly, the proportion of B cells was significantly elevated within type 2 diabetic islets. CONCLUSIONS/ INTERPRETATION: Elevated total islet leucocyte content and proinflammatory mediators correlated with islet dysfunction, suggesting that heterogeneous insulitis occurs during the development of islet dysfunction in type 2 diabetes. In addition, the altered B cell content highlights a potential role for the adaptive immune response in islet dysfunction.
Authors: D A Taylor-Fishwick; J R Weaver; W Grzesik; S Chakrabarti; S Green-Mitchell; Y Imai; N Kuhn; J L Nadler Journal: Diabetologia Date: 2012-10-03 Impact factor: 10.122
Authors: Jessica R Weaver; Theodore R Holman; Yumi Imai; Ajit Jadhav; Victor Kenyon; David J Maloney; Jerry L Nadler; Ganesha Rai; Anton Simeonov; David A Taylor-Fishwick Journal: Mol Cell Endocrinol Date: 2012-03-20 Impact factor: 4.102
Authors: Jason DeFuria; Anna C Belkina; Madhumita Jagannathan-Bogdan; Jennifer Snyder-Cappione; Jordan David Carr; Yanina R Nersesova; Douglas Markham; Katherine J Strissel; Amanda A Watkins; Min Zhu; Jessica Allen; Jacqueline Bouchard; Gianluca Toraldo; Ravi Jasuja; Martin S Obin; Marie E McDonnell; Caroline Apovian; Gerald V Denis; Barbara S Nikolajczyk Journal: Proc Natl Acad Sci U S A Date: 2013-03-11 Impact factor: 11.205
Authors: Claudia Cavelti-Weder; Andrea Babians-Brunner; Cornelia Keller; Marc A Stahel; Malaika Kurz-Levin; Hany Zayed; Alan M Solinger; Thomas Mandrup-Poulsen; Charles A Dinarello; Marc Y Donath Journal: Diabetes Care Date: 2012-06-14 Impact factor: 19.112
Authors: Hannah M Gordon; Neil Majithia; Patrick E MacDonald; Jocelyn E Manning Fox; Poonam R Sharma; Frances L Byrne; Kyle L Hoehn; Carmella Evans-Molina; Linda Langman; Kenneth L Brayman; Craig S Nunemaker Journal: Endocrine Date: 2017-04-12 Impact factor: 3.633
Authors: Jonathan R Weitz; Carol Jacques-Silva; Mirza Muhammed Fahd Qadir; Oliver Umland; Elizabeth Pereira; Farhan Qureshi; Alejandro Tamayo; Juan Dominguez-Bendala; Rayner Rodriguez-Diaz; Joana Almaça; Alejandro Caicedo Journal: Diabetes Date: 2020-04-03 Impact factor: 9.461